Predicting high-risk rhabdomyosarcoma at diagnosis to improve outcomes
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Detecting lingering brain cancer cells before a tumour grows back
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
Discovering what makes teenagers and young adults with soft tissue sarcomas different
Finding the biological differences between teenage and young adult cancers cells compared to older adults.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
Liquid biopsies for rhabdomyosarcoma: A new way to improve rhabdomyosarcoma treatment
Looking for differences in newly diagnosed RMS patient samples to see if there are any that could be used to show whether treatments are working.
Finding a low-cost way to detect endemic Burkitt Lymphoma earlier
Helping children in sub-Saharan Africa with endemic Burkitt Lymphoma get diagnosed earlier.
Developing a 'better than MRI scan' test for ependymoma
Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer